85.7 percent had objective tumor response after guardant360® test
Published 3 years ago • 153 plays • Length 0:22Download video MP4
Download video MP3
Similar videos
-
1:06
what is guardant360 response™ and how does treatment monitor testing work?
-
0:54
you've taken your guardant360 response™ test - what's next?
-
0:23
guardant360 test’s 7 days turnaround time
-
0:22
guardant360® detects more guideline-recommended biomarkers than tissue testing
-
0:22
guardant360® test results show more than 90% agreement with tissue (findings from nile study)
-
0:50
understand guardant360 response™: is my cancer treatment working?
-
0:58
leading oncologist shares his thoughts fda-approved guardant360® cdx liquid biopsy test
-
1:14
what is guardant reveal™ & how can it help monitor my cancer treatment?
-
1:06
breast cancer patient case– where the guardant360® test was used
-
3:03
colorectal cancer patient case - where the guardant360® test was used
-
4:06
lung cancer patient cases – where the guardant360® test was used
-
2:00
findings from plasmamatch study - using guardant360® liquid biopsy
-
2:28
nile study findings using guardant360® liquid biopsy
-
0:37
what to expect after your guardant360® cdx cgp test
-
0:56
you've taken your guardant reveal™ test - what's next?
-
0:54
guardant reveal™ launch
-
0:42
how can liquid biopsies like guardant360®️ help guide treatment decisions for advanced stage cancer?
-
0:24
guardant360’s comprehensive genotyping in nsclc